February, 2022 | News & Updates

Summary : Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous…

February 2022

Expert: Newly Appointed FDA Commissioner Robert Califf Is Perfectly Positioned to Advance the FDA’s Accelerated Approval Pathway

NICE recommends cenobamate for treatment of adult epilepsy patients in UK

Moderna’s commercial network grows

Scancell gains new facilities at The Oxford Science Park

Repurposing FDA-approved drugs may help combat COVID-19

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

ADDING MULTIMEDIA Capri EGM Acquires R&D Build-to-Suit for National Resilience, a Biomanufacturing Company Contracted by the DOD, Harvard, and Moderna

GC Pharma Receives Complete Response Letter From the U.S. FDA For ‘ALYGLO’

Syniverse Is First to Offer a Cloud-Native, Hyperscale Digital Communications and Messaging Platform for Enterprises: Syniverse’s Hyperscale Communications Platform

Data delivery: Sanofi and GSK seek authorisation for COVID-19 vaccine